A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model

Langroudi, Ladan; Hassan, Zuhir Muhammad; Ebtekar, Massoumeh; Mahdavi, Mehdi; Pakravan, Nafise; Noori, Shokoofe

doi:10.1016/j.intimp.2010.06.005

Cited by 46 publications

(39 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Langroudi et al [119] Implanted mouse spontaneous mammary ductal carcinoma, started when tumors reached 500 mm 3 Ma et al [199] A549 human non-small cell lung carcinoma mouse xenograft; started when tumors reached 100 mm 3 , artesunate (60 or 120 mg/kg/day, p.o., 2 weeks).…”

Section: Lai Andmentioning

confidence: 99%

“…Noori and Hassan [118] further reported that dihydroartemisinin decreased IL-4 and the level of CD4(+)CD25(+)Foxp3 (+) T-lymphocytes in mice. Laugroudi et al [119] reported that artemisinin reduced Treg cells in tumor and increased IFN gamma/IL-4 ratio in splenoctye cultures. Increase in Treg cells in tumors is correlated with tumor progression.…”

Section: Lai Andmentioning

confidence: 99%

See 1 more Smart Citation

Development of artemisinin compounds for cancer treatment

2012

View full text Add to dashboard Cite

Artemisinin contains an endoperoxide moiety that can react with iron to form cytotoxic free radicals. Cancer cells contain significantly more intracellular free iron than normal cells and it has been shown that artemisinin and its analogs selectively cause apoptosis in many cancer cell lines. In addition, artemisinin compounds have been shown to have anti-angiogenic, anti-inflammatory, anti-metastasis, and growth inhibition effects. These properties make artemisinin compounds attractive cancer chemotherapeutic drug candidates. However, simple artemisinin analogs are less potent than traditional cancer chemotherapeutic agents and have short plasma half-lives, and would require high dosage and frequent administration to be effective for cancer treatment. More potent and target-selective artemisinin-compounds are being developed. These include artemisinin dimers and trimers, artemisinin hybrid compounds, and tagging of artemisinin compounds to molecules that are involved in the intracellular iron-delivery mechanism. These compounds are promising potent anticancer compounds that produce significantly less side effect than traditional chemotherapeutic agents.

show abstract

Section: Lai Andmentioning

confidence: 99%

Section: Lai Andmentioning

confidence: 99%

Development of artemisinin compounds for cancer treatment

2012

View full text Add to dashboard Cite

show abstract

“…In the present study, we explored the cytotoxic and immunostimulatory effects of artemether in comparison with cyclophosphamide as the positive control [35].…”

Section: Introductionmentioning

confidence: 99%

Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo

Farsam

Hassan

Zavaran-Hosseini

et al. 2011

International Immunopharmacology

Self Cite

View full text Add to dashboard Cite

“…In a murine model of breast cancer, artemisinin decreased Treg counts and elevated the splenocyte IFNc/IL-4 ratio, reflecting its immunoenhancing properties [68]. In Schistosoma mansoni-infected mice, a combination of artemether and praziquantel shifted the ratio of Th/cytotoxic cells to Th differentiation and improved liver functions [69].…”

Section: Artemisinins and T-cellsmentioning

confidence: 99%